To The Moon

Favourite $CRDF in open positions

🔺🅱️🆄🅻🅻🅸🆂🅷📈🔬🧬 CRDF: Brewing a Biotech Breakout 🧬🔬📈

Kia ora Tiger traders!

Cardiff Oncology (CRDF) is showing some intriguing moves, but will it deliver the goods or leave us hanging? With its current setup, this could be the trade that turns a few dollars into a jackpot! 🚀📊 Let’s dive into the latest data, chart insights, and market chatter to find out!

📊 Tech Check: The CRDF Chart Rundown 📊

   •   Current Price: $2.83 (Market Closed, 25 Oct) 📉

   •   Post-Market: $2.94 (+3.89%) 📈

   •   52-Week High: $6.42

   •   52-Week Low: $0.94

   •   Volume: 573.8K

The chart is teasing a classic cup and handle formation, a beloved signal among technical traders. 🏆☕ With eyes set on $3.24 as a breakout target, a successful breach could send CRDF soaring! With the right momentum, this stock could triple its value, pushing towards $8.50 and beyond, mirroring past patterns of aggressive growth in the biotech sector. 📈🚀 Is this the breakout you’ve been waiting for?

💼 Earnings & Financials: Improving, but Still in the Red 💼

   •   Q2 EPS Loss: -$0.26 (vs. expected -$0.25) 🔴

   •   Revenue: $0.16M (35.83% above estimates) 📈

   •   2024 H1 EPS: -$0.49 (better than -$0.93 in 2023 FY)

Despite the ongoing losses, CRDF has outperformed revenue expectations 4 times in a row. It’s a slow but steady grind up, and those with a long-term vision might see potential where others see volatility. 📉➡️📈

🟢 Positives: Consistent revenue growth, R&D advances, sector tailwinds.

🔴 Negatives: EPS still in negative territory, high short interest (~42.84%).

🧠📊 Analyst Ratings: Majority Bullish, But Caution Remains 🧠📊

   •   🟢 Strong Buy: 20%

   •   🟢 Buy: 80%

   •   🟡 Hold: 0%

   •   🔴 Sell: 0%

The sentiment is overwhelmingly positive—80% of analysts recommend buying, hinting at a promising future. Some analysts are hinting at the potential for this stock to triple if it can break free of its resistance zones. However, the Zacks Rank #3 (Hold) suggests caution. The high short interest could lead to volatility, but also a potential short-squeeze scenario. 🏹💣

💸 Capital Flow & Trading Sentiment 💸

CRDF’s turnover rate of 1.33% reflects moderate but stable trading activity. Post-market action shows a bump to $2.94 (+3.89%), signalling renewed interest. Traders are watching key levels:

📍 Resistance:

   •   $3.24 (Major Target) 🚧 (The breakout could see CRDF surge towards $8.50)

   •   $3.01 (Immediate Resistance)

🔽 Support:

   •   $2.66 (MA30 Strong Support)

   •   $2.73 (Recent Low)

A decisive push past $3.24 could ignite a bullish trend, while a drop below $2.66 may indicate the bears are still in control. 🔄🔮

🏆 Competitive Edge: Where Does CRDF Stand? 🏆

1. Moderna (MRNA)

      •   🟢 Buy: 70%

      •   🟡 Hold: 20%

      •   🔴 Sell: 10%

      •   Trend: Riding FDA approvals; solid revenue growth 🌟

2. BioNTech (BNTX)

      •   🟢 Buy: 60%

      •   🟡 Hold: 30%

      •   🔴 Sell: 10%

      •   Trend: Strong partnerships; bullish sentiment 🤝📈

3. Gilead Sciences (GILD)

      •   🟢 Buy: 50%

      •   🟡 Hold: 40%

      •   🔴 Sell: 10%

      •   Trend: Mixed trial results, robust cash flow 📉💸

CRDF might be a small fish in a big pond, but don’t underestimate its resilience. Will it be the biotech sleeper hit? 🏅🧬💡

🌟 BC’s Final Word: High Stakes or High Potential? 🌟

CRDF is like a Kiwi surfing the biotech waves—risky, thrilling, and unpredictable! 🌊🏄 With the right setup, this stock has the potential to triple in value, making it one to watch. If you’re keen on a potential breakout, now’s the time to keep a close watch on the $3.24 mark. A smooth sail or a wipeout? Only time will tell! 🏄🕶️

Hey Tiger Traders, are you betting on a breakout or waiting for clearer signs? 🤔📈📉

@TigerGPTcould you analyse the historical trends of biotech stocks forming a cup and handle, particularly in high-short-interest environments? 🧠📊

Happy trading ahead. Cheers, BC 🍀